Related Experiment Videos
Proventil HFA and ventolin have similar safety profiles during regular use
D G Tinkelman1, E R Bleecker, J Ramsdell
1Department of Medicine, University of Maryland, Baltimore, USA.
Chest
|March 14, 1998
Summary
Proventil HFA and Ventolin showed similar safety profiles to placebo in asthma patients over 12 weeks. Regular use of these inhaled bronchodilators did not worsen asthma control.
Area of Science:
- Pulmonology
- Pharmacology
- Clinical Trials
Background:
- Asthma management relies on inhaled beta-adrenergic bronchodilators.
- Evaluating the safety of new inhalant formulations is crucial for patient care.
Purpose of the Study:
- To assess the safety and tolerability of Proventil HFA (albuterol) and Ventolin compared to a hydrofluoroalkane 134a (HFA-134a) placebo.
- To evaluate the impact of regular dosing on asthma control over a 12-week period.
Main Methods:
- A randomized, double-blind, double-dummy, placebo-controlled, multicenter trial.
- Asthmatics received Proventil HFA, Ventolin, or HFA-134a placebo four times daily for 12 weeks.
- Safety was monitored through adverse event reporting, peak expiratory flow, symptom scores, rescue medication use, vital signs, and laboratory tests.
Main Results:
- Adverse event rates were comparable across all treatment groups.
- Active treatments showed trends towards improved daytime symptom scores and evening peak expiratory flow compared to placebo.
- No significant differences in nighttime sleep disturbance, vital signs, or laboratory tests were observed.
Conclusions:
- Proventil HFA and Ventolin demonstrate a similar safety profile to each other and to the HFA-134a placebo.
- Regular use of Proventil HFA or Ventolin does not negatively impact asthma control.
- The HFA-134a placebo, at 16 puffs/day, was well-tolerated by asthma patients.